Resources

Gemini Bioproducts, LLC (“GeminiBio”), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne.

Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, today announced the launch of new products designed to improve cell therapy manufacturing processes.

GeminiBio announces the launch of a new human AB serum product for the cell therapy and regenerative medicine markets.

CEO of California Life Sciences with extensive and varied experience across the life science ecosystem.

Senior biopharma and cell therapy engineering/operations executive with 30+ years of experience to help drive growth

Projected growth to more than double by 2025

Asahi Kasei Bioprocess America and GeminiBio enter strategic partnership to advance application of Inline Buffer Formulation and streamline biopharmaceutical manufacturing processes. The strategic partnership will establish a joint solution for the efficient creation of buffers created from concentrates delivered directly to manufacturing facilities, increasing productivity and speed to market. • Costs for biopharmaceutical production can be significantly reduced, positively affecting the accessibility of medication for patients globally. • This partnership will be a catalyst for innovation at both companies, driving new industry standards.

GeminiBio opens new cGMP bioprocess liquid manufacturing facility, expanding capabilities to better serve the biotechnology and cell & gene therapy markets

Gemini BioProducts Holding, Inc. (“GeminiBio” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, and BroadOak Capital Partners, a life science focused investment firm, announced today the appointment of Bryan Poltilove to the Board of Directors.